Key result
ACE2 counter-regulates ACE signaling, emerging as a potential therapeutic target in diabetic complications.
Why the study?
Activation of the renin angiotensin system contributes to diabetic complications, but blockade of Ang II slows but does not prevent progression, and the role of ACE2 in diabetes is not well understood.
Design
Review of current data on ACE2 in diabetes
Authors
Loading...
Challenges classical Ang II-centric RAS view; leaves open whether ACE2/Ang 1-7 targeting alters cardiovascular outcomes.
ACE2 represents a potential novel therapeutic target for modulating the renin-angiotensin system to prevent or treat cardiac and renal complications in diabetes.
Dean et al. (2007) conducted a review in Diabetic complications. ACE2 was evaluated. ACE2 acts in a counter-regulatory manner to ACE to modulate vasoconstrictors and vasodilators, presenting a novel therapeutic target for the prevention and treatment of diabetic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: